Advaxis Inc. to Present at the LD Micro Growth Conference in Los Angeles, CA

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Apr 3, 2008 - Advaxis Inc., (OTCBB: ADXS, http://www.advaxis.com.), a developmental biotechnology company, will present at the LD Micro Growth Conference in Los Angeles, CA on Tuesday, April 29th at 10:00 AM PDT.

Presenting on behalf of the company will be Thomas Moore, Advaxis' chairman and CEO. Key parts of the presentation will include Mr. Moore's detailing efficacy data in human patients; the company's catalogue of live Listeria monocytogenes ("Lm") constructs; and significant corporate developments.

"We are looking forward to presenting at our first investor conference of 2008," said Mr. Moore. "We will review several new developments, including new constructs, and collaborations. We will also be updating the investment community on the continued progress of our clinical program. Sharing our progress with financial decision makers can support our efforts toward reducing our time to market for our many promising clinical candidates and increasing our value for our shareholders."

About LD Micro

Founded in 2000, LD Micro is a boutique equity research firm focused on providing research coverage for mostly micro- and small- cap clients. From time to time, the firm may invest in-house funds on select clients. For more information, please visit www.ldmicro.com.

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.

Advaxis' lead Lm vaccine candidate - Lovaxin C - targets cervical and head and neck cancers. Current Lm vaccines in development target prostate, breast, ovarian and lung cancers. Advaxis has completed a Phase I/II clinical trial. The Lm platform will also have applications in the fields of infectious disease and autoimmune disorders.

For further information on the Company, please visit: http://www.advaxis.com.

About Lovaxin C Vaccine

Advaxis' Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Lm, combined with Advaxis' proprietary fusion protein, has the ability to generate a robust immune response and produce an unusually strong and effective multi-level therapeutic immune response to existing cancers and other diseases.

Advaxis' Lm-based technology is mostly based on Dr. Yvonne Paterson's decade worth of work in her laboratory at the University of Pennsylvania. The Company's proprietary antigen fusion protein technology, also suppresses regulatory T cells that inhibit many vaccines in the creation of activated tumor-killing cells.

Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus ("HPV") infection, which is the most prevalent sexually transmitted disease in the US. Current prophylactic products on the market are ineffective in treating HPV-infected women.

For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Contact

The Investor Relations Group
Investor Relations
Conrad F. Mir, 212-825-3210
conrad@investorrelationsgroup.com
or
Christine Berni
christine@investorrelationsgroup.com
or
Public & Media Relations
Janet Vasquez
janet@investorrelationsgroup.com
or
Michaela Heller
michaela@investorrelationsgroup.com

Posted: April 2008

View comments

Hide
(web5)